Belo M, Yagello M, Girard M, Greenlee R, Deslandres A, Barré-Sinoussi F, Gluckman J C
Laboratoire de Biologie et Génétique des Déficits Immunitaires, CERVI, UFR Pitié-Salpêtrière, Paris, France.
AIDS. 1991 Feb;5(2):169-76. doi: 10.1097/00002030-199102000-00006.
After immunization of chimpanzees against HIV antigens, antibodies that mediate antibody-dependent cellular cytotoxicity (ADCC) were evaluated and compared with anti-HIV-antibody levels detected by enzyme-linked immunosorbent assay (ELISA) and neutralizing antibody titers. Adult chimpanzees were immunized with different HIV-1 (LAV-BRU) antigen preparations: recombinant vaccinia virus (rVV) expressing gp160, p25 or p27nef; formalin- and beta-propiolactone-inactivated whole virus (inHIV); soluble recombinant gp160 either associated or not associated with other HIV proteins; a 25-mer peptide from the V3 region of gp120 coupled with KLH (V3-KLH). Immunization with the various rVV mixtures induced no or borderline ADCC increase above preimmune serum levels. Stronger and more sustained reactivity was elicited by inHIV. Purified HIV antigens elicited ADCC activity when the chimpanzees were naive; ADCC increased or remained at the same level when the animals had been preimmunized with rVV and/or inHIV. This type of reactivity apparently did not depend on whether gp160 alone or mixed with other proteins was used for immunization. The injection of V3-KLH resulted in only little, if any, recall ADCC response. ELISA antibody titers significantly correlated with ADCC and neutralizing antibody titers, but serum ADCC was independent of neutralizing antibody titers, an indication that the two latter serum activities are mediated by independent antibodies. Therefore, ADCC is elicited in the same manner as other antibody activities by the immunization of chimpanzees with inHIV or with purified recombinant HIV antigen preparations. The results obtained from the three chimpanzees of this series, which were subsequently challenged with infectious virus through the intravenous route, suggest that serum ADCC may be considered for vaccination purposes.
在用HIV抗原免疫黑猩猩后,对介导抗体依赖性细胞毒性(ADCC)的抗体进行了评估,并与通过酶联免疫吸附测定(ELISA)检测到的抗HIV抗体水平和中和抗体滴度进行了比较。成年黑猩猩用不同的HIV-1(LAV-BRU)抗原制剂进行免疫:表达gp160、p25或p27nef的重组痘苗病毒(rVV);经福尔马林和β-丙内酯灭活的全病毒(inHIV);与其他HIV蛋白相关或不相关的可溶性重组gp160;与钥孔血蓝蛋白(KLH)偶联的来自gp120 V3区的25聚体肽(V3-KLH)。用各种rVV混合物免疫后,ADCC没有增加或仅略微高于免疫前血清水平。inHIV引发了更强且更持久的反应。当黑猩猩未接触过抗原时,纯化的HIV抗原可引发ADCC活性;当动物预先用rVV和/或inHIV免疫后,ADCC增加或保持在相同水平。这种反应类型显然不取决于单独使用gp160还是与其他蛋白质混合用于免疫。注射V3-KLH仅引发了极少的(如果有的话)回忆性ADCC反应。ELISA抗体滴度与ADCC和中和抗体滴度显著相关,但血清ADCC与中和抗体滴度无关,这表明后两种血清活性是由独立的抗体介导的。因此,通过用inHIV或纯化的重组HIV抗原制剂免疫黑猩猩,ADCC的引发方式与其他抗体活性相同。从该系列的三只黑猩猩获得的结果表明,随后通过静脉途径用感染性病毒进行攻击,血清ADCC可用于疫苗接种目的。